Dr Lal PathLabs (DLPL IN): Strong Trajectory in Non-COVID Business; Positive Industry Outlook
Dr Lal PathLabs reported 14% and 16%, YoY, non-COVID revenue growth in 4QFY23 and FY23, respectively. Due to lesser competitive threat and recent...
246 Views
Prodia (PRDA IJ) - Back to Core Testing
Prodia (PRDA IJ) FY2022 results saw declines in revenues and profits but from a COVID-high base and the numbers are now well-above 2019, with...
457 Views
Prodia (PRDA IJ) - A Standout in Diagnostics
Prodia (PRDA IJ) stands out in terms of its strong market positioning and track record together with attractive valuations, especially versus...
327 Views
Agilus Diagnostics Limited Pre-IPO - Still Recovering from COVID
Agilus Diagnostics Limited (SRLL IN) is looking to raise around US$200m in its upcoming India IPO. In this note, we talk about the company's past...
359 Views
Prodia (PRDA IJ) - Diagnosing a Return to Healthy Profits
Prodia (PRDA IJ) is significantly cheaper than its Indian comparables, trading on half the valuation, despite being a high-quality player tapping...
514 Views